Vernal keratoconjunctivitis market, share, trends, epidemiological forecast to 2030
The “Vernal Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast-2030” report from DelveInsight provides an in-depth understanding of Vernal Keratoconjunctivitis, historical and predicted epidemiology, and United States Vernal Keratoconjunctivitis market trends, in EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
Vernal keratoconjunctivitis (VKC) is a bilateral allergic inflammation of the conjunctiva, usually seasonally recurring, characterized by limbal gelatinous hypertrophy and / or giant conjunctival papillae of the superior tarsus.
the Vernal Keratoconjunctivitis Market The report provides current treatment practices, emerging drugs, individual therapies vernal keratoconjunctivitis market share, current and forecasted vernal keratoconjunctivitis market size from 2017 to 2030 segmented by seven major markets. The report also covers the current practice / algorithm for treating vernal keratoconjunctivitis, market drivers, market barriers and unmet medical need to best manage opportunities and assess the underlying potential of the market.
Vernal Keratoconjunctivitis Market Overview
the vernal keratoconjunctivitis (VKC) market size on total contracts in 2017 was USD 307.89 million
Drivers of the vernal keratoconjunctivitis market
- Increase in prevalence
- Disease awareness and diagnosis
- Research and development
Obstacles to the vernal keratoconjunctivitis market
- Weak pipeline of emerging drugs
- Diagnostic barriers
- Limited approved therapies
Vernal Keratoconjunctivitis Market Outlook
The treatment of VKC requires several approaches that include conservative measures and pharmacological treatment. Patients and parents should be informed about the prolonged duration of the disease, its chronic course and possible complications. Treatment should be based on the duration and frequency of symptoms and the severity of the corneal damage.
The topical drugs currently available for allergic conjunctivitis belong to several pharmacological classes, such as vasoconstrictors, antihistamines, mast cell stabilizers, ‘double acting‘ agents (with antihistamine and mast cell stabilization properties), nonsteroidal anti-inflammatory drugs, corticosteroids, and immunosuppressive drugs.
Mast cell stabilizers are the first-line drugs for VKC. Several studies have demonstrated the effectiveness of 2% and 4% sodium cromoglicate (DSCG, cromolyn), nedocromil sodium 2%, lodoxamide tromethamine 0.1%, and spaglumic acid 4%.
Eye drugs with antihistamine activity may offer therapeutic benefits to patients with allergic conjunctivitis, including VKC, by inhibiting the secretion of pro-inflammatory cytokines by conjunctival epithelial cells. First generation antihistamines pheniramine and antazoline have a long safety record. Newer antihistamines such as 0.5% levocabastine hydrochloride and 0.05% emedastine difumarate have a longer duration of action (4 to 6 hours) and are better tolerated than their predecessors.
A meta-analysis of randomized clinical trials with VKC showed that a large number of studies evaluated the effectiveness of common anti-allergic eye drops (levocabastine, lodoxamide, mipragoside, N-acetyl aspartyl glutamic acid, nedocromil sodium, GCD). Among these, lodoxamide seemed to be the most effective.
Papilock mini and Verkazia both produced by Santen (Osaka, Japan) are specifically indicated for the treatment of VKC.
Generally, NSAIDs used in the treatment of eye allergies inhibit both the enzymes cyclooxygenase (COX) -1 and COX-2. Too, Ketorolac, diclofenac and pranoprofen may be valid alternatives to steroids, as they have a proven effect on itching, intercellular adhesion molecule-1 expression, and tear tryptase levels. Indomethacin 1%, ketorolac 0.5% and diclofenac 0.1% have been shown to be effective in the treatment of VKC.
Aspirin 0.5 to 1 g / day has been shown to be a steroid sparing factor in the treatment of VKC; however, it should be used with caution due to the well-known possible side effects.
In severe cases, systemic treatment with inhibitors of T cell signal transduction such as cyclosporin A or tacrolimus may improve both dermatological and ocular manifestations in critical patients who are refractory to conventional therapy.
Omalizumab, a humanized, non-anaphylactogenic, recombinant anti-IgE antibody directed against the IgE receptor binding domain can be used in patients with VKC with elevated serum total IgE levels. Calcineurin inhibitors are non-Marketing Authorized treatments in the European Union.
As discussed, the current treatment of VKC depends solely on the use of antihistamines, mast cell inhibitors and several other classes. But so far the treatment is only supportive and not so effective. But due to advances in technology and a better understanding of the disease, several companies are trying to change treatment for VKC.
Request sample pages @ Vernal Keratoconjunctivitis (VKC) Market Report
1. Key information
2. Executive summary of vernal keratoconjunctivitis (VKC)
3. Vernal keratoconjunctivitis (VKC): market overview at a glance
3.1. Total market share (%) Distribution of VKC in 2017
3.2. Total market share (%) Distribution of VKC in 2030
4. Background and overview of the disease: vernal keratoconjunctivitis (VKC
5. Case report
6. Epidemiology and patient population
7. Epidemiology of the United States
8. UE5 Epidemiology
8.1. Assumptions and rationale
8.2. Germany Epidemiology
8.3. France Epidemiology
8.4. Italy Epidemiology
8.5. Spain Epidemiology
8.6. United Kingdom Epidemiology
9. Epidemiology of Japan
10. Epidemiology of the MEA region
10.1. Assumptions and rationale
10.2. Saudi Arabia’s epidemiology
10.3 Epidemiology of Egypt
11. Epidemiology of China
12. Russia Epidemiology
13. Current treatment and medical practices
13.1. Treatment of VKC
13.2. Convenient management of VKC
13.3. Treatment guidelines
14. Unmet needs
15. Medicines marketed
15.1. Verkazia / Verkacia: Santen
15.2. Lodoxamide / Alomide: Novartis Pharmaceuticals / Alcon
15.3. Talymus / Tacrolimus: Senju Pharmaceutical
16. Emerging drugs
16.1. Antolimab (AK002): Allakos
16.2. Bertilimumab / iCo-008: iCo Therapeutics
16.3. Nomacopan: Akari Therapeutics
17. Vernal keratoconjunctivitis (VKC): market analysis of 7 MM
18. United States
19. EU-5 countries
19.1 Germany market size
19.2 Size of the French market
19.3 Size of the Italian market
19.4 Spain market size
19.5 UK Market Size
20.1. Japanese market size
21. Market Outlook for MEA Countries
21.1.Saudi Arabia Market Size
21.2 Egypt Market Size
22. China: Market Outlook
22.1. Chinese market size
23. Russian market outlook
23.1. Russia market size
24. Market drivers
25. Market barriers
26. Reimbursement and market access
27. SWOT analysis
28. KOL Views
30. Capabilities of DelveInsight
32. About DelveInsight
Company Name: SearchInsight
Contact person: Shruti Thakur
E-mail: Send an email
Address:304, boulevard S. Jones # 2432
City: Las Vegas
Country: United States